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Abstract
Background: We have shown that intravenous adenosine in normal subjects does not cause
bronchospasm, but causes dyspnea, most likely by an effect on vagal C fibers in the lungs [Burki et
al. J Appl Physiol 2005; 98:180-5]. Since airways inflammation and bronchial hyperreactivity are
features of asthma, it is possible that intravenous adenosine may be associated with an increased
intensity of dyspnea, and may cause bronchospasm, as noted anecdotally in previous reports.
Methods: We compared the effects of placebo and 10 mg intravenous adenosine, in 6 normal and
6 asthmatic subjects.
Results: Placebo injection had no significant (p > 0.05) effect on the forced expiratory spirogram,
heart rate, minute ventilation (Ve), or respiratory sensation. Similarly, adenosine injection caused
no significant changes (p > 0.05) in the forced expiratory spirogram; however, there was a rapid
development of dyspnea as signified visually on a modified Borg scale, and a significant (p < 0.05)
tachycardia in each subject (Asthmatics +18%, Normals + 34%), and a significant (p < 0.05) increase
in Ve (Asthmatics +93%, Normals +130%). The intensity of dyspnea was significantly greater (p <
0.05) in the asthmatic subjects.
Conclusion: These data indicate that intravenous adenosine does not cause bronchospasm in
asthmatic subjects, and supports the concept that adenosine-induced dyspnea is most likely
secondary to stimulation of vagal C fibers in the lungs. The increased intensity of adenosine-induced
dyspnea in the asthmatic subjects suggests that airways inflammation may have sensitized the vagal
C fibers.
Background
The respiratory effects of adenosine, and endogenous
nucleoside, have been studied in animals and man. Ade-
nosine is also used therapeutically to treat supraventricu-
lar tachycardia [1]. Amongst the reported side effects [2]
of intravenous adenosine in asthmatics are bronchos-
pasm and dyspnea; however, in normal subjects we have
shown [3] that while intravenous adenosine is dyspno-
genic, and also stimulates ventilation and tachycardia, it
does not cause bronchospasm. In rats we have shown that
intravenous adenosine directly stimulates pulmonary
vagal C fibers through activation of A1 receptors [4], and it
is likely that the dyspnea in man is a direct consequence
of pulmonary C fiber activation. Asthmatic subjects are
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known to have airways inflammation hyperreactivity and
it is probable that airway vagal fibers are sensitized in
these subjects.
We therefore studied normal subjects and asthmatics, to
document whether the intensity of adenosine-induced
dyspnea is altered in asthma and whether it is associated
with bronchospasm.
Methods
We studied six healthy normal subjects, and 6 subjects
with mild to moderate persistent asthma [5]. They were all
non-smokers and the asthmatic subjects were selected on
the basis of a history of asthma [5], and airways obstruc-
tion (FEV1/FVC < 70%), with significant response (∆ FEVI
> +15%) to inhaled bronchodilator. The asthmatic sub-
jects (Mean age ± sd: 40.0 ± 11.0 years; three females)
were all non-smokers. One subject had exercise-induced
asthma and only used inhaled beta agonists prior to exer-
cise, with irregular, occasional use of inhaled steroids; all
the other subjects were on regular inhaled steroid treat-
ment, with inhaled beta – agonists used either on a regular
two to four times daily basis (2 subjects) or used as
needed for symptomatic relief. None of the subjects had
had any acute exacerbations of asthma within the previ-
ous 3 months. Baseline FVC was 97.0 ± 20.6% of the pre-
dicted value (range 69% – 119%), and FEV1 was 65.3 ±
12.2% of the predicted value (range 54% to 95%). All
subjects were asked to refrain from using any beta-agonist
drugs or caffeine containing beverages for 12 hours before
the study day. Written informed consent as approved by
the IRB was obtained from each subject.
Each subject was seated and a forearm vein was cannu-
lated and connected to a normal saline drip. A curtain
between the subject and the cannulated forearm pre-
vented the subject from being able to see when an injec-
tion was given (see below). Ventilation, ventilatory
pattern, and forced expiratory spirograms [6] were
recorded with the subject breathing via a mouthpiece
attached to a two-way valve (Hans-Rudolph, Kansas City,
MO); expiratory flow was recorded on a multi-channel
recorder (Grass Medical Instruments, Astro-Med Inc, West
Warwick, RI) as the differential pressure signal from a
heated pneumotachygraph on the expiratory side of the
valve, connected to a differential pressure transducer
(Hans-Rudolph, Kansas City, MO). The flow signal was
electronically integrated to volume and recorded. The sys-
tem was calibrated before each experiment, using a cali-
brated syringe (Spirometrix, Inc).
End-tidal CO2 was sampled at the mouthpiece through a
needle attached to a CO2 meter (Ohmeda, Englewood,
CO), the output from which was continuously recorded.
Arterial O2 saturation (SaO2) and heart rate were recorded
continuously using a pulse oximeter (Criticare Systems,
Inc. Waukesha, WI).
Measurements of dyspnea were made using a modified
Borg scale [7] to which the subject pointed. The subjects
were asked to focus on respiratory symptoms such as chest
tightness, shortness of breath, increased urge to breathe,
burning sensation in the chest and throat; preliminary
studies had indicated that the commonest symptoms
expressed were shortness of breath and chest tightness.
Each subject received either an injection of placebo (nor-
mal saline), followed by adenosine, 10 mg, or vice versa;
the sequence was randomized, and subjects and observers
were blinded to the sequence.
Baseline spirometry measurements were made and when
the subject had a stable breathing pattern (as judged by
<5% variation in the end-tidal CO2), minute ventilation
(Ve), ventilatory pattern, end-tidal CO2, heart rate (H.R.),
and SaO2 were recorded over three minutes, and a base-
line Borg score was recorded.
The subject then received the injection of placebo or ade-
nosine, care being taken to avoid awareness of the injec-
tion by the subject. Measurements of ventilation, end-
tidal CO2, SaO2 and HR were made continuously over the
next 15 minutes. Borg scores were recorded immediately
after the injection and every 20 seconds thereafter for the
next 5 minutes. Spirometry was measured at baseline, and
at 3 minutes, 5 minutes, 10 minutes and 15 minutes post
injection. Thirty minutes after the first injection, a second
injection of either placebo or adenosine was given, and
further measurements made for another 15 minutes.
Statistical analysis of the data within each group was per-
formed by repeated measures one way ANOVA [8]. Com-
parison between groups was by two-way ANOVA [8].
Comparison of baseline values between the groups was
performed by unpaired t test.
Results
As expected, the FEV1, FVC, and FEV1/FVC values were
significantly (p < 0.03) lower in the asthmatic versus the
normal subjects (Table 1)
Neither saline injection nor intravenous adenosine
resulted in any significant change (p > 0.5) in the spiro-
gram (Table 1).
Placebo injection resulted in no significant (p > 0.5)
change in Ve, ventilatory pattern, end-tidal CO2, SaO2 or
HR, and no subject indicated any change in the Borg
score.
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On the other hand, adenosine injection resulted in signif-
icant increases in Ve and heart rate in both groups (Figure
1).
All subjects experienced an increase in respiratory sensa-
tion after the adenosine injection, represented by an
increase in the Borg dyspnea score (Fig 1). The changes in
Borg dyspnea score were evident within 20–40 seconds,
which was also the time of peak intensity of the dyspnea;
in verbalizing the sensation after intravenous adenosine,
9 subjects described "chest tightness", 7 subjects described
the sensation as "shortness of breath/difficulty in breath-
ing" and 3 subjects described constriction in the throat.
The increase in HR and Ve occurred slightly later, and
peaked within the first 40–60 seconds after adenosine
injection. The dyspnea, as well as the tachycardia and
increased ventilation returned to baseline within 3 min-
utes of the injection. The initial intensity of the dyspnea
was significantly greater (p < 0.05) and of longer duration
in the asthmatic subjects (Figure 1).
Discussion
The present study confirms our previous results in normal
subjects [3] that intravenous adenosine is dyspnogenic
and results in an increase in ventilation and tachycardia,
and extends these observations to asthmatics.
Intravenous infusion of adenosine is known to increase
heart rate by increasing cardiac sympathetic tone [1,9-11];
this effect overrides the bradycardia caused by its direct
effects on the sinus node and atrio-ventricular conduc-
tion. In normal subjects we have shown [3] that adenos-
ine causes tachycardia; the results of the present study are
in conformity with these previous reports: intravenous
adenosine was associated with a significant tachycardia.
The ventilatory effects of adenosine have previously been
ascribed to activation of carotid chemoreceptors [9,11];
however, our previous data [3] indicate that the ventila-
tory effects of adenosine are probably not secondary to
carotid chemoreceptor stimulation per se.
There are anecdotal reports [1,2] of bronchospasm in
asthmatics receiving intravenous adenosine for the treat-
ment of arrhythmia. However bronchoconstriction has
never been documented by any measurements of airway
function. In a study [12] of 122 consecutive patients,
undergoing adenosine stress testing for myocardial per-
fusion imaging, of whom 36 had chronic bronchitis, dys-
pnea was noted in over 50% of subjects but no changes in
spirometric indices were noted. Previous studies have
found no change in airway function in normal subjects
[1,3] after intravenous adenosine, and our results are in
conformity with these findings, and further extend these
observations to asthmatic subjects, since there was no sig-
nificant change in the spirogram after adenosine. Thus it
is probable that dyspnea in asthmatics receiving intrave-
nous adenosine has been misinterpreted as bronchocon-
striction in these instances.
Inhaled adenosine and adenosine 5-monophosphate and
triphosphate are known to cause bronchospasm in asth-
matics probably via mast cell mediator release [13-16]
and, since this effect has not been demonstrated with
intravenous adenosine [1,3,12], this suggests that the
bronchospastic effect of adenosine is related to the route
of administration. The bronchospasm occurring with
inhaled adenosine monophosphate and triphosphate is
also associated with the development of dyspnea; this has
been interpreted as being secondary to the bronchospasm,
although differences in the intensity of dyspnea for equiv-
alent degrees of bronchospasm have been ascribed to an
additional effect on airway sensory nerves [15,16].
Dyspnea, or shortness of breath [17-19], is a common
accompaniment of most lung diseases, however, this sen-
sation remains poorly understood and a number of theo-
ries have been put forth as to the genesis of this sensation
Table 1: Spirometry in Normal & Asthmatic Subjects (Mean ± SD)
Normals Asthmatics
Placebo Adenosine Placebo Adenosine
Baseline Post p Baseline Post p Baseline Post p Baseline Post p
FEV1, L 3.63 ± 0.49 3.61 ± 0.51 ns 3.63 ± 0.56 3.67 ± 0.59 ns 2.66 ± 0.75 2.61 ± 0.85 ns 2.68 ± 0.78 2.71 ± 0.84 ns
FVC, L 4.53 ± 0.65 4.48 ± 0.60 ns 4.47 ± 0.71 4.50 ± 0.72 ns 4.09 ± 0.88 4.02 ± 1.00 ns 4.09 ± 1.00 4.10 ± 1.00 ns
FEV1/FVC,% 80.0 ± 3.0 80.3 ± 3.4 ns 81.5 ± 3.6 83.5 ± 2.4 ns 65.3 ± 12.9 65.2 ± 14.5 ns 66.0 ± 12.7 55.0 ± 12.9 ns
Baseline and Post-bronchodilator values significantly different (p < 0.03) between normal and asthmatic subjects.
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Effects of adenosine in normal and asthmatic subjectsFigure 1
Effects of adenosine in normal and asthmatic subjects. Mean ± SEM. ❍ = normal subjects, ●  = asthmatic subjects. * = difference 
from baseline p < 0.05, repeated measures ANOVA φ = difference from Normals, p < 0.05, two way ANOVA
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[17,18]. The currently accepted view central, chemorecep-
tor, and peripheral (chest wall mechanoreceptor and lung
receptor) mechanisms [18-20]. The present study exam-
ined the role of lung receptors in the genesis of dyspnea.
Sensory receptors in the lungs are innervated by the vagus
nerves and consist of three types: stretch receptors and irri-
tant receptors in the large airways, and unmyelinated
vagal C fibers [21]. While the irritant receptors appear to
modify the intensity of dyspnea associated with induced
bronchoconstriction [22], and the airway stretch receptors
appear to modify breathlessness by altering ventilatory
pattern [23,24], neither of these receptors has been shown
to be specifically dyspnogenic.
Vagal afferent C fibers have been implicated in the sensa-
tion of dyspnea [26]. These are small, unmyelinated nerve
fibers that provide sensory input from airway and lung
structures. These nerve endings are believed to lie in close
proximity to the pulmonary capillaries and alveoli, and
are also present in the bronchiolar epithelium of the con-
ducting airways [21]. Pulmonary C fibers are now consid-
ered synonymous [25,26] with the "J" receptors described
by Paintal [27] in the lung parenchyma. Some workers
[21] have subdivided the C fibers into two groups, pulmo-
nary and bronchial, whereas other investigators [28,29]
have disputed this. It is also unclear whether there are dif-
ferences in receptor properties between the two groups.
Stimulation of pulmonary vagal C fibers in animals
results in apnea followed by tachypnea, airway smooth
muscle contraction, mucus hypersecretion, and extravasa-
tion of macromolecules into the tracheobronchial tree
[30]. In man, pulmonary C fibers have been implicated in
the sensation of dyspnea [31], although direct evidence of
this has been hard to obtain [32]. Human studies attempt-
ing to characterize C fibers have utilised intravenous
lobeline or intravenous or aerosolized capsaicin; these
produce coughing and burning or irritating sensations in
the throat and midsternum [25,27,33-35]. These sensa-
tions are often so powerful that they limit the dose of the
drug that can be administered. No attempt was made in
these studies to differentiate the contributions from pul-
monary and bronchial C fibers and the development of a
cough raises the possibility that other receptors, such as
the irritant receptors may also be stimulated by these
drugs [25].
In normal human subjects, bilateral local anesthetic block
of the vagus nerves at the base of the skull diminished
breathholding sensation, and prolonged breathholding
[36]; in dyspneic patients, bilateral vagal blockade
reduced the intensity of dyspnea, but did not totally
relieve the dyspnea [37,38]. In normal subjects, exercise-
induced breathlessness is reduced, but not abolished, by
local anesthetic blockade of alveolar receptors [32]. In
contrast, in dyspneic patients with various lung diseases,
local anesthesia of the airways did not modify the dysp-
nea, although the level and extent of airway anesthesia
achieved is uncertain [39,40]. However, small particle aer-
osol-induced anesthesia of the smaller airways in rats
abolished the tachypnea induced by microemboli, sug-
gesting that vagal C fibers were involved in the tachypnea
[32]. Evidence implicating a role for airway/alveolar C fib-
ers in dyspnea comes from studies of nebulized morphine
in dypneic patients [41] which reduced exercise induced
dyspnea, and the finding of an increase in exercise
induced dyspnea in normal subjects after inhalation of
prostaglandin E2, which is known to increase vagal affer-
ent C fiber sensitivity [42]. Thus, while previous evidence
is suggestive, the results of studies of dyspnea and the role
of pulmonary vagal C fibers have been inconclusive.
A study in rats in our laboratory [4] provided the first evi-
dence that adenosine stimulates pulmonary C fibers
through activation of A1 receptors. We extended these
studies to normal human subjects [3,43] and showed that
intravenous adenosine induces significant dyspnea in the
absence of changes in airways resistance, and in associa-
tion with an increase in ventilation. In these studies, we
used hand grip dynamometry to assess respiratory sensa-
tion, and the interrupter technique for measuring airways
resistance, which allowed us to closely examine the time
latencies of these effects. We found that the dyspnogenic
response was not related to the ventilatory or cardiac
response and, as in the present study, preceded the venti-
latory and cardiac responses. We concluded that the dysp-
nea is secondary to a direct effect of adenosine on vagal C
fibers in the lung [3]. However, handgrip dynamometry
does not allow comparison of the intensity of sensation
between subjects, therefore in the present study we used
the modified Borg scale and found that the intensity of
dyspnea after intravenous adenosine was increased in
asthmatics versus normal subjects.
The fact that the cardiac and ventilatory responses were
significantly less in the asthmatic subjects in the present
study, whereas the dyspnea rating had a greater intensity,
lends further support to the concept that the dyspneic
response is not related to the ventilatory or cardiac effects
of adenosine and is probably not mediated by the carotid
chemoreceptors, and supports the concept that it is most
likely secondary to stimulation of vagal C fibers in the
lungs. The increased intensity of dyspnea in the asthmat-
ics may represent a lowered threshold of activation and/or
a higher sensitivity of the C fibers, consequent to the air-
way inflammation in asthma.
Dyspnea is a cardinal symptom of asthma, but the precise
mechanism of the dyspnea is unknown [44]. It has been
Respiratory Research 2006, 7:139 http://respiratory-research.com/content/7/1/139
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shown [15] that dyspnea in asthmatics is directly related
to the degree of airways obstruction in any given patient;
however, between asthmatics, equivalent degrees of
obstruction do not elicit equivalent degrees of dyspnea
[15,16]. Furthermore, the intensity of dyspnea is directly
related to the relationship between the minute ventilation
and the central inspiratory neuromuscular drive: the
lower this ratio, the greater the dyspnea [15].
It has been suggested [44] that dyspnea in asthma is due
to a combination of the increased sense of effort second-
ary to the increased mechanical load, with an additional
contribution from afferent receptors in the airways or
lungs. Most workers have suggested that the latter are
most likely the rapidly adapting irritant receptors in the
airways [44-46]. However, these conclusions are based on
the results of inhaled lidocaine blockade of the airways,
although there is no way to assess from these studies
whether there was also some partial blockade of the air-
way and pulmonary C receptors. Since airway inflamma-
tion is a cardinal feature of asthma [47] it is possible that
inflammation stimulates the C fiber endings in the lungs
and airways, resulting in dyspnea. The present study
results would support such a conclusion.
In conclusion, this study has shown that intravenous ade-
nosine results in dyspnea both in normal and asthmatic
subjects, and that this effect is not related to bronchos-
pasm. Adenosine also causes an increase in ventilation;
however the dyspnogenic effect is clearly not a conse-
quence of the increase in ventilation. Asthmatic subjects
have a greater intensity of dyspnea in response to adenos-
ine, perhaps secondary to sensitization of the airway vagal
C fibers due to airways inflammation. The timing of the
dyspnogenic response indicates that it is not related to
carotid chemoreceptor stimulation and is most likely a
consequence of direct stimulation of pulmonary vagal C
fibers.
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